Liquid biopsies may identify patients with residual subclinical disease after systemic therapy and after induction systemic therapy followed by LRT.49, 50, 51 Numerous cancer-related molecules such as cell-free DNA, circulating tumor DNA (ctDNA), blood TMB, allelic variants from ctDNA, circulating tumor cells, neutrophil to lymphocyte ratio, and soluble PD-L1 can be characterized in liquid biopsies.50 The gene discussed is CD274; the disease is neoplasm.